Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.62 |
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | GLS | O94925 | 3/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634225 | 0.87 | GHSR (0.67) | GHSRTACR1ABCB1MEN1LMNA | |
| SCHEMBL3638183 | 0.85 | GHSR (0.71) | GHSRTACR1ABCB1LMNAHTT | |
| SCHEMBL13044525 | 0.83 | GHSR (0.68) | GHSRTACR1ABCB1KMT2ATACR3 | |
| Formic Acid SCHEMBL3737752 | 0.82 | GHSR (0.66) | GHSRTACR1ABCB1LMNAHTT | |
| SCHEMBL3635203 | 0.82 | GHSR (0.74) | GHSRTACR1TACR3 | |
| SCHEMBL3634458 | 0.81 | GHSR (0.69) | GHSRTACR1ABCB1LMNA | |
| SCHEMBL3637403 | 0.80 | GHSR (0.68) | GHSRTACR1LMNAKMT2A | |
| SCHEMBL13078785 | 0.80 | GHSR (0.58) | GHSRTACR1ABCB1MEN1KMT2A | |
| SCHEMBL3633192 | 0.79 | SLC6A2 (0.51) | SLC6A2MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL13044526 | 0.79 | GHSR (0.61) | GHSRTACR1LMNAPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | claimed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | GHSR 2/4885TACR1 56/4885SLC6A2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.